University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Pharmacological interventions for fatigue in cancer and transplant meta-analysis

Tomlinson, D., Robinson, P.D., Oberoi, S., Cataudella, D., Culos-Reed, N., Davis, H., Duong, N., Gibson, Faith, Götte, M., Hinds, P. , Nijhof, S.., van der Torre, P., Dupuis, L.L. and Sung, L. (2017) Pharmacological interventions for fatigue in cancer and transplant meta-analysis Current Oncology.

[img] Text
Pharmacological interventions - manuscript.pdf - Accepted version Manuscript
Restricted to Repository staff only

Download (449kB)

Abstract

Background: Objective was to determine whether pharmacological interventions reduce the severity of fatigue in patients with cancer or hematopoietic stem cell transplant (HSCT) recipients as compared to control interventions.

Methods: We conducted a systematic review and searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, CINAHL and PsychINFO for randomized trials of systemic pharmacological interventions for the management of fatigue in patients with cancer or HSCT recipients. Two authors independently identified studies and abstracted data. Methodological quality was assessed using the Cochrane Risk of Bias tool. Primary outcome was fatigue severity across different fatigue scales. Data were synthesized with random effects models.

Results: There were 117 trials (19,819 patients) included. Pharmacological agents were: erythropoietins (n=31); stimulants (n=19); L-carnitine (n=6); corticosteroids (n=5); anti-depressants (n=5), appetite-stimulants (n=3) and other agents (n=48). Erythropoietin (standardized mean difference (SMD) -0.52, 95% confidence interval (CI) -0.89 to -0.14) and methylphenidate (SMD -0.36, 95% CI -0.56 to -0.15) significantly reduced fatigue while modafinil/armodafinil and corticosteroids were not effective.

Conclusions: Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in HSCT recipients. Concerns regarding the safety of these agents may limit their usefulness. Future research should identify effective interventions for fatigue with minimal adverse effects.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Health Sciences
Authors :
NameEmailORCID
Tomlinson, D.UNSPECIFIEDUNSPECIFIED
Robinson, P.D.UNSPECIFIEDUNSPECIFIED
Oberoi, S.UNSPECIFIEDUNSPECIFIED
Cataudella, D.UNSPECIFIEDUNSPECIFIED
Culos-Reed, N.UNSPECIFIEDUNSPECIFIED
Davis, H.UNSPECIFIEDUNSPECIFIED
Duong, N.UNSPECIFIEDUNSPECIFIED
Gibson, Faithf.gibson@surrey.ac.ukUNSPECIFIED
Götte, M.UNSPECIFIEDUNSPECIFIED
Hinds, P.UNSPECIFIEDUNSPECIFIED
Nijhof, S..UNSPECIFIEDUNSPECIFIED
van der Torre, P.UNSPECIFIEDUNSPECIFIED
Dupuis, L.L.UNSPECIFIEDUNSPECIFIED
Sung, L.UNSPECIFIEDUNSPECIFIED
Date : 2017
Copyright Disclaimer : Copyright © 2017 Multimed Inc.
Uncontrolled Keywords : Pharmacological agents; Fatigue; Meta-analysis; Drugs; Oncology; Cancer related fatigue; Erythropoietins; Stimulants; Corticosteroids
Related URLs :
Depositing User : Clive Harris
Date Deposited : 30 Nov 2017 16:02
Last Modified : 30 Nov 2017 16:02
URI: http://epubs.surrey.ac.uk/id/eprint/845085

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800